MYNDR Launches an AM/PM Brain Supplement for Perimenopause

MYNDR is a new direct-to-consumer supplement brand built around a single, specific customer: women in perimenopause who are dealing with brain fog, lost focus, and memory slips. Instead of a general nootropic or a broad women’s health formula, the brand sells a two-part daily system, MYNDR AM and MYNDR PM, plus a companion tracking app.

This is the first entry in our Launch Radar series, where we look at new DTC brands from an operator’s point of view. Not a review, just notes on what the brand is trying and what the rest of us can borrow.

What MYNDR is selling

MYNDR positions itself under the line “Cognitive Support for Perimenopause.” The core idea, repeated throughout the site, is that perimenopause is a neurological event as much as a hormonal one. Estrogen fluctuations affect neurotransmitters, and the brand argues that the cognitive symptoms deserve a product designed for them rather than a footnote in a multivitamin.

The product is a 30-day system with two formulas:

Formula	When	Role the brand describes
MYNDR AM	Morning	Focus and daytime clarity
MYNDR PM	Evening	Overnight support, aligned to the body’s daily rhythm

The tagline that ties it together is “Your brain runs on a cycle. So does MYNDR.” The brand highlights transparent dosing, third-party testing, and says most customers should notice a difference within 14 to 21 days of continuous use. The launch offer is a discounted 30-day system with free U.S. shipping and a 60-day money-back guarantee.

Why the positioning works

Most supplement launches try to cover as many use cases as possible. The homepage promises energy, focus, immunity, and sleep, and ends up meaning nothing to anyone. MYNDR does the opposite, and it is the most interesting thing about the launch.

The customer is one person. Women roughly 35 to 50 who have noticed their focus and memory change. The copy speaks to that person directly and names the experience: you blamed sleep, you blamed stress, and neither explanation held up. That specificity does a lot of work. It makes ad creative easy to write, it makes the product feel built for the reader, and it makes the brand the obvious answer when that reader searches for what is happening to her.

The category is underserved. Menopause has become a real DTC category over the last few years, but most of it is about hot flashes, sleep, and hormone support. Cognitive symptoms are widely reported and rarely the headline. Owning that gap is cheaper than fighting for “menopause supplement” as a whole.

The system framing raises the stakes. Selling AM and PM together instead of one bottle changes what the customer is buying. It is a routine, not a pill. That matters for pricing, because a system justifies a higher ticket than a single SKU, and it matters for retention, because a twice-daily habit tied to morning and night is much stickier than “take one with food.”

The retention mechanics worth copying

The parts of this launch that operators should study are the ones that happen after checkout.

The app closes the loop. A tracking app for a supplement is unusual for a brand this new. It gives customers a way to log how they feel, which is exactly what a product with a two to three week onboarding window needs. It also gives MYNDR first-party data on whether the product is working, which is more useful than any review widget.

The 14 to 21 day promise sets the flow. When you tell a customer to expect a change in the third week, your post-purchase email and SMS flow has to carry her there. The critical messages land between day 10 and day 21: what to expect this week, what to log in the app, and what other customers noticed at this point. A discount code at day 14 would be the wrong move. Reassurance is the right one. This is Klaviyo work, and it is the kind of flow an email and SMS partner like Branva builds for Shopify brands that do not yet have a lifecycle marketer.

The guarantee outlasts the promise. A 60-day money-back guarantee on a product that claims results in three weeks is deliberate. It tells a skeptical buyer that the brand is willing to be wrong for twice as long as it expects to need. In a category where trust is the whole game, that is the cheapest credibility a new brand can buy.

What to watch

• Subscription conversion. A 30-day system is a natural subscription, and the launch offer is a one-time discount. How the brand moves first-time buyers onto a recurring plan, and whether it uses skip and pause rather than hard cancellation, will decide the economics.
• Creative that survives scrutiny. Cognitive claims in a women’s health category will draw attention from ad platforms and regulators. The brand’s emphasis on transparent dosing and third-party testing is a good foundation, but the ad creative has to stay on the right side of “supports” versus “treats.”
• Expansion pressure. Once a brand owns a symptom, the temptation is to add sleep, mood, and joint products. The right sequencing is to deepen the cognitive line first, with the app as the moat, before widening.

Bottom line

MYNDR’s launch is a case study in picking a life stage instead of a demographic. “Women 35 to 50” is a demographic. “Women whose focus changed and nobody could tell them why” is a customer. The AM/PM system, the tracking app, and the long guarantee all point at the same goal: turn a supplement into a routine before the first bottle runs out.

• Launching in a crowded category? Find the symptom nobody is leading with and own it.
• Selling anything with an onboarding curve? Build the day 10 to day 21 flow before you build the welcome series.
• Making a results claim? Make the guarantee longer than the claim.